Home/Biosimilar Atlas/Ranibizumab/Zenotech ranibizumab

Zenotech ranibizumab

Ranibizumab biosimilar developed by Zenotech Laboratories. Reference product Lucentis.

Brands by market: Brand not published by CDSCO (India) · Commercial partner or holder: Zenotech Laboratories · Company profile
FDANot listed
EMANot listed
MHRANot listed
PMDANot listed
HCNot listed
CDSCOOct 2023permitted
EDENot listed
Approved or registered in 1 of 7 markets
Connections
RanibizumabmoleculeZenotech Laboratoriesdeveloper1 of 7markets0trials behind it1other products, same developer5rival developers in its markets

About Zenotech ranibizumab

Zenotech received its ranibizumab permission in India in October 2023 for wet macular degeneration, its second biosimilar after rituximab.

Status by market

FDA

United States

Not listed by FDA.

EMA

European Union

Not listed by EMA.

MHRA

United Kingdom

Not listed by MHRA.

PMDA

Japan

Not listed by PMDA.

HC

Canada

Not listed by HC.

CDSCO

India

Central Drugs Standard Control OrganisationApproved
Brand
Not published by CDSCO (INN only)
Holder or applicant
Zenotech Laboratories Limited
Pathway
Similar Biologic, manufacture and marketing permission
Approved
Oct 2023
Application or permission
MF/BIO/23/000089
Indications as licensed
Wet AMD
Presentations
10 mg/mL single-use vial
Source
S011 (CDSCO) · checked Sep 2026
EDE

United Arab Emirates

Not listed by EDE.

Other developers in the same markets

Where Zenotech ranibizumab holds an approval, these are the other ranibizumab biosimilars approved in that market.

MarketRivalsDevelopers (product)
CDSCO5Enzene Biosciences (Enzene Biosciences ranibizumab), Intas Pharmaceuticals (Rexatilux / Razumab), Lupin (Ranluspec / Vislyfa), Reliance Life Sciences (Reliance Life Sciences ranibizumab), Sun Pharmaceutical Industries (Sun Pharma ranibizumab)

Same developer, other molecules

Other biosimilars in the Atlas developed by Zenotech Laboratories: Zenotech rituximab.

Chronology

Sources

All ranibizumab biosimilars

Planning ranibizumab biosimilar development?

EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.

Talk to a biosimilar regulatory consultant
Data current to September 2026.